Tumor spectrum in ARF-deficient mice

Cancer Research

Volumn 59, Issue 9, 1999, Pages 2217-2222

  Kamijo, Takehiko ^b   Bodner, Sara ^b   Van De Kamp, Esther ^b   Randle, David H ^b   Sherr, Charles J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; PROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN ARF; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOMA; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; GENE LOSS; HETEROZYGOTE; IRRADIATION; LYMPHOMA; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOMA; CELL LINEAGE; COCARCINOGENESIS; DISEASE PROGRESSION; FEMALE; FIBROSARCOMA; GENE DELETION; GENES, P53; GENOTYPE; LOSS OF HETEROZYGOSITY; LYMPHOMA; MALE; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NEOPLASMS, NERVE TISSUE; NEOPLASMS, RADIATION-INDUCED; NUCLEAR PROTEINS; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TIME FACTORS; TUMOR STEM CELLS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033135110     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R., and Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22: 3551-3555, 1994.
2. INK4a/CDKN2A tumor suppressor and its relatives. BBA Rev. Cancer, 1378: F115-F177, 1998.
3. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
4. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
5. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
6. Sherr, C. J. Tumor surveillance via the ARF-p53 pathway. Genes Dev., 12: 2984-2991, 1998.
7. Serrano, M., Lee, H-W., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. A. Role of the INK4a locus in tumor suppression and cell mortality. Cell, 85: 27-37, 1996.
8. ARF. Cell, 91: 649-659, 1997.
9. CDJN2 expresion and its implications for cell immortalization and senescence. Mol. Cell. Biol., 16: 859-867, 1996.
10. Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., and Barrett, J. C. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA, 93: 13742-13747, 1996.
11. INK4a. Cell, 88: 593-502, 1997.
12. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene, 15: 203-211, 1997.
13. Kemp, C. J., Wheldon, T., and Balmain, A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet., 8: 66-69, 1994.
14. Pattengale, P. K., and Firth, C. H. Contributions of recent research to the classification of spontaneous lymphoid neoplasms in mice. Crit. Rev. Toxicol., 16: 185-212, 1986.
15. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA, 95: 8292-8297, 1998.
16. Robertson, K. D. and Jones, P. A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol., 18: 6457-6473, 1998.
17. Reiners, J. J., Jr., Nesnow, S., and Slaga, T. J. Murine susceptibility to two-stage skin carcinogenesis is influenced by the agent used for promotion. Carcinogenesis (Lond.), 5: 301-307, 1984.
18. Naito, M., and DiGiovanni, J. Genetic background and development of skin tumors. In: C. J. Conti, T. J. Slaga, and A. J. P. Klein-Szanto (eds.), Carcinogenesis, Vol III: Skin Tumors: Experimental and Clinical Aspects, pp. 187-212. New York: Raven Press, 1989.
19. Kamijo, T., van de Kamp, E., Chong, M. J., Zindy, F., Diehl, J. A., Sherr, C. J. and McKinnon, P. J. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled Atm function. Cancer Res., 59: in press, 1999.
20. Westphal, C. H., Hoyes, K. P., Canman, C. E., Huang, X., Kastan, M. B., Hendry, J. H., and Leder, P. Loss of atm radiosensitizes multiple p53 null tissues. Cancer Res., 58: 5637-5639, 1998.
21. Gardie, B., Cayuela, J. M., Martini, S., and Sigaux, F. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood, 91: 1016-1020, 1998.
22. Look, A. T., Roberson, P. K., Williams, D. L., Rivera, G., Bowman, W. P., Pui, C-H., Ochs, J., Abramowitch, M., Kalwinsky, D., Dahl, G. V., George, S., and Murphy, S. B. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood, 65: 1079-1086, 1985.
23. 1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev., 12: 3675-3685, 1998.
24. Hayashi, Y., Ueki, K., Waha, A., Wiestler, O. D., Louis, D. N., and von Deimling, A. Association of EGFR gene amplification and CDKN2 (p16/MTSI) gene deletion in glioblastoma multiforme. Brain Pathol., 7: 871-875, 1997.
25. He, J., Olson, J. J., and James, C. D. Lack of p16NK4 or retinoblastoma protein (pRb) or amplification associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res., 55: 4833-4836, 1995.
26. Lang, F. F., Miller, D. C., Koslow, M., and Newcomb, E. W. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. Neurosurgery, 81: 427-436, 1994.
27. Louis, D. N., von Deimling, A., Chung, R. Y., Rubio, M., Waley, J. M., Eibl, R. H., Ohgaki, H., Wiestler, O. D., Thor, A. D., and Seizinger, B. R. Comparative study of p53 gene and protein alterations in human astrocytic tumors. Neuropathol. Exp. Neurol., 52: 31-38, 1993.
28. Rasheed, B. K., McLendon, R. E., Herndon, J. E., Friedman, H. S., Friedman, A. H., Bigner, D. D., and Bigner, S. H. Alterations of the TP53 gene in human gliomas. Cancer Res., 54: 1324-1330, 1994.
29. Schlegel, J., Merdes, A., Stumm, G., Albert, F. K., Forsting, M., Hynes, N., and Kiessling, M. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behavior in human glioblastoma. Int. J. Cancer, 56: 72-77, 1994.
30. 1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. Genes Dev., 12: 3644-3649, 1998.
31. Knudson, A. G., Jr., Hethcote, H. W., and Brown, B. W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. Natl. Acad. Sci. USA, 72: 5116-5120, 1975.
32. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
33. ARF with Mdm2 inhibits ubiquitin ligase activity of MDM2 for tumor suppressor p53. EMBO J., 18: 22-27, 1999.
34. Roth, J., Dobbelstein, M., Freedman, D., Shenk, T., and Levine, A. J. Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17: 554-564, 1998.
35. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
36. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.
37. Harvey, M., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. A., Bradley, A., and Donehower, L. A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet., 5: 225-229, 1993.
38. Nacht, M., Strasser, A., Chan, Y. R., Harris, A. W., Schlissel, M., Bronson, R. T., and Jacks, T. Mutations in p53 and SCID genes cooperate in tumorigenesis. Genes Dev., 10: 2055-2066, 1996.
39. Liao, M., Zhang, X-X., Hill, R., Gao, J., Qumsiyeh, M. B., Nichols, W., and Van Dyke, T. No requirement for V(D)J recombination in p53-deflcient thymic lymphoma. Mol. Cell. Biol., 18: 3495-3501, 1998.
40. Nacht, M., and Jacks, T. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ., 9: 131-138, 1998.